NCT04515836View on ClinicalTrials.gov

Olaparib in Patients With HRD Malignant Mesothelioma

PHASE2RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

April 15, 2028

Study Completion Date

April 15, 2028

Conditions

MesotheliomaHomologous Recombination Deficiency

Interventions

DRUG

Olaparib

Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.

Trial Locations (1)

60615

RECRUITING

University of Chicago Medical Center, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

University of Chicago

OTHER